Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
ID | DOID:5517 |
Name | stomach carcinoma |
Definition | A stomach cancer that is located_in the stomach. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer gastrointestinal system cancer stomach cancer stomach carcinoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
Unknown unknown | Tivantinib | stomach carcinoma | not applicable | detail... |
FGFR2 act mut | S-49076 | stomach carcinoma | sensitive | detail... |
ERBB2 positive | Tucatinib | stomach carcinoma | sensitive | detail... |
CDKN2A R80* | Palbociclib | stomach carcinoma | sensitive | detail... |
Unknown unknown | SST0116CL1 | stomach carcinoma | not applicable | detail... |
ERBB2 positive | Trastuzumab Duocarmazine | stomach carcinoma | sensitive | detail... |
FGFR2 amp | PRN1371 | stomach carcinoma | sensitive | detail... |
FGFR2 amp | RO4987655 | stomach carcinoma | no benefit | detail... |
FGFR2 amp | RO5126766 | stomach carcinoma | no benefit | detail... |
ERBB2 amp | Debio 1347 | stomach carcinoma | no benefit | detail... |
FGFR2 amp | Debio 1347 | stomach carcinoma | sensitive | detail... |
Unknown unknown | MGCD516 | stomach carcinoma | not applicable | detail... |
BRAF mutant | KO-947 | stomach carcinoma | predicted - sensitive | detail... |
NRAS mutant | KO-947 | stomach carcinoma | predicted - sensitive | detail... |
STK11 Y253* STK11 dec exp | Sirolimus | stomach carcinoma | predicted - sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01174121 | Phase II | Pembrolizumab Cyclophosphamide + Fludarabine Aldesleukin | Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer | Suspended | USA | 0 |
NCT01183559 | Phase I | Carboplatin + Fluorouracil + Paclitaxel + Vandetanib | A Trial of ZD6474 (Zactima), Paclitaxel, Carboplatin, 5-Fluorouracil, and XRT Followed by Surgery | Completed | USA | 0 |
NCT02065765 | Phase II | Ramucirumab | International Expanded Access Program to Provide Ramucirumab for the Treatment of Metastatic Gastric Cancer | No longer available | 5 | |
NCT02274012 | Phase II | Afatinib + Paclitaxel | Trial of Afatinib in Combination With Weekly Paclitaxel in the Second Line Treatment of HER2 Amplified Advanced Gastric, Gastroesophageal Junction and Esophageal Cancer | Withdrawn | 0 | |
NCT02344810 | Phase Ib/II | AMG 337 Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab | C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal Cancer | Withdrawn | USA | 0 |
NCT02488759 | Phase Ib/II | Nivolumab | A Study to Investigate the Safety and Efficacy of Nivolumab in Virus-associated Tumors (CheckMate358) | Active, not recruiting | USA | 10 |
NCT02611024 | Phase Ib/II | Irinotecan + Lurbinectedin | Pharmacokinetic Study of PM01183 in Combination With Irinotecan in Patients With Selected Solid Tumors | Recruiting | USA | 1 |
NCT02773524 | Phase III | Regorafenib | A Study of Regorafenib in Refractory Advanced Gastro-Oesophageal Cancer (INTEGRATEII) | Recruiting | USA | CAN | 5 |
NCT02830594 | Phase II | Pembrolizumab | Pembrolizumab and Palliative Radiation Therapy in Treating Patients With Metastatic Esophagus, Stomach, or Gastroesophageal Junction Cancer | Active, not recruiting | USA | 0 |
NCT02892123 | Phase I | Capecitabine + ZW25 ZW25 Paclitaxel + ZW25 Vinorelbine + ZW25 | Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers | Recruiting | USA | CAN | 1 |
NCT03008278 | Phase Ib/II | Olaparib + Ramucirumab | Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery | Recruiting | USA | 0 |
NCT03076372 | Phase I | MM-310 | A Study Evaluating MM-310 in Patients With Solid Tumors | Unknown status | USA | 0 |
NCT03288350 | Phase II | Cisplatin + Docetaxel + Fluorouracil Avelumab | mDCF + Avelumab in Resectable Esophago-gastric Adenocarcinoma (EGA) | Recruiting | CAN | 0 |
NCT03474640 | Phase I | Toripalimab | Safety, Tolerability and Pharmacokinetics of an Anti-PD-1 Monoclonal Antibody in Subjects With Advanced Malignancies | Recruiting | USA | 0 |
NCT03957096 | Phase I | SGN-CD47M | A Safety Study of SGN-CD47M in Patients With Solid Tumors | Terminated | USA | 0 |
NCT04096638 | Phase I | Nivolumab + SB 11285 SB 11285 | Evaluating Safety and Efficacy of SB 11285 Alone and in Combination With Nivolumab in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT04140526 | Phase Ib/II | ONC-392 ONC-392 + Pembrolizumab | Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC | Recruiting | USA | 0 |
NCT04254107 | Phase I | SGN-TGT Pembrolizumab + SGN-TGT | A Safety Study of SGN-TGT in Patients With Advanced Cancer | Recruiting | USA | 4 |
NCT04594811 | Phase II | Nivolumab Nivolumab + NT-I7 | NT-I7 in Combination With Nivolumab in Advanced Gastric, Gastro-Esophageal Junction or Esophageal Adenocarcinoma | Recruiting | USA | 0 |